Mason Carrico
Stock Analyst at Stephens & Co.
(2.06)
# 2,896
Out of 4,761 analysts
62
Total ratings
33.96%
Success rate
-0.92%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACB Pacific Biosciences of California | Reiterates: Overweight | $2.5 | $1.54 | +62.34% | 4 | Feb 18, 2025 | |
| HOLX Hologic | Reiterates: Overweight | $84 | $64.49 | +30.25% | 3 | Feb 6, 2025 | |
| FNA Paragon 28 | Downgrades: Equal-Weight | $14 → $13 | $13.02 | -0.15% | 1 | Jan 30, 2025 | |
| MYGN Myriad Genetics | Reiterates: Equal-Weight | $20 | $14.18 | +41.04% | 4 | Jan 16, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $65 | $52.00 | +25.00% | 1 | Jan 15, 2025 | |
| CSTL Castle Biosciences | Reiterates: Overweight | $41 | $25.75 | +59.22% | 7 | Jan 2, 2025 | |
| ILMN Illumina | Maintains: Overweight | $170 → $184 | $94.20 | +95.33% | 6 | Nov 12, 2024 | |
| TXG 10x Genomics | Reiterates: Overweight | $30 | $10.90 | +175.23% | 5 | Oct 10, 2024 | |
| NTRA Natera | Reiterates: Overweight | $125 | $162.31 | -22.99% | 4 | Aug 9, 2024 | |
| NEO NeoGenomics | Reiterates: Overweight | $19 | $11.10 | +71.17% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $44 | $42.87 | +2.64% | 4 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $22.29 | -19.25% | 8 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $4 | $2.65 | +50.94% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $5.12 | +75.78% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.05 | +339.02% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $39.18 | -13.22% | 6 | Oct 10, 2023 |
Pacific Biosciences of California
Feb 18, 2025
Reiterates: Overweight
Price Target: $2.5
Current: $1.54
Upside: +62.34%
Hologic
Feb 6, 2025
Reiterates: Overweight
Price Target: $84
Current: $64.49
Upside: +30.25%
Paragon 28
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $14 → $13
Current: $13.02
Upside: -0.15%
Myriad Genetics
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $14.18
Upside: +41.04%
Vericel
Jan 15, 2025
Reiterates: Overweight
Price Target: $65
Current: $52.00
Upside: +25.00%
Castle Biosciences
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $25.75
Upside: +59.22%
Illumina
Nov 12, 2024
Maintains: Overweight
Price Target: $170 → $184
Current: $94.20
Upside: +95.33%
10x Genomics
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $10.90
Upside: +175.23%
Natera
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $162.31
Upside: -22.99%
NeoGenomics
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $11.10
Upside: +71.17%
May 24, 2024
Reiterates: Overweight
Price Target: $44
Current: $42.87
Upside: +2.64%
May 13, 2024
Maintains: Overweight
Price Target: $15 → $18
Current: $22.29
Upside: -19.25%
Apr 17, 2024
Reiterates: Equal-Weight
Price Target: $4
Current: $2.65
Upside: +50.94%
Dec 14, 2023
Initiates: Overweight
Price Target: $9
Current: $5.12
Upside: +75.78%
Nov 13, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.05
Upside: +339.02%
Oct 10, 2023
Reiterates: Overweight
Price Target: $34
Current: $39.18
Upside: -13.22%